Adolescent Idiopathic Scoliosis (AIS)MID-CNCT03071471
Feasibility Evaluation Study of the MID-C Device
An observational study of Adolescent Idiopathic Scoliosis (AIS), run by Apifix at 1 site in Israel.
Trial summary
Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle . Read more about this study
- Who is it for?
- Ages 11 to 17 years
- Conditions the study is for
- Adolescent Idiopathic Scoliosis (AIS)
- What is being tested?
- MID-C
- Type of treatment
- Medical device
- How many people
- 7 participants
- Where
- 1 siteIsrael
- Study dates
- Jun 2014to Jul 2016
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 11 to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: The study is designed as a European, observational study with a 12-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 6-month enrollment period.
Who may be able to join
- Adolescence aged 11 years old to 17 years inclusive
- Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5, with flexible secondary curve.
- Completed at least 6 months of conservative therapy (e.g., P.T., bracing, traction, or others).
- Risser sign of 1 to 4
- Appropriate candidate for posterior surgical approach
- Subject has Good general health.
- Subject has no hypersensitivity and allergies to Titanium
- Subject guardians willing to sign a written informed consent form (ICF).
Who cannot join
- Cobb angle over 55 degrees
- Other non idiopathic scoliosis.
- AIS which is not defined as Lenke type 1 or 5
- Previous spine surgery.
- Allergy to any component of the device.
- Active systemic disease, such as AIDS, HIV, or active infection
Show all 9Show fewer
- Back or leg pain of unknown etiology Page 9 of 18
- Systemic disease that would affect the subject's welfare or overall outcome of the study.
- Mentally compromised
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)
Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle .
The Cobb angle measurement of scoliosis represents the sum of the angular wedging of each vertebra and disc between the superior and inferior end vertebrae . Although a small curve is well tolerated and does not require treatment, a large curve can progress to the point that it is cosmetically unacceptable, interferes with chest wall mechanics, and produces cardiac and pulmonary compromises. The natural history of AIS apparently includes 2 stages: the initiation of the curve and its subsequent progression. The factors responsible for the initiation of the curve are unknown, but the subsequent progression of the curve is clearly associated with the adolescent growth spurt . The primary risk factors for progression include age at onset and the magnitude of the curve; young patients with large curves are at the highest risk .
Read more
Although numerous treatment methods have been recommended for patients with AIS, the only accepted treatment includes bracing for skeletally immature patients with curves between 25 and 40 degrees and operative correction with spinal fusion for patients with curves greater than 45 degrees. For many teenagers, the cosmetic and social concerns associated with bracing has caused compliance problems with wearing the brace and many patients only wear the brace at home . While operative intervention completely corrects the scoliosis or rib hump, it eliminates segmental spinal motion, and concentrates stresses at the ends of the fusion potentially leading to disc degeneration and back pain.
Despite satisfactory short-term results of operative instrumentation and fusion, a less invasive technique preserving more motion with a smaller scar represents a major improvement. Realizing this goal is contingent on treating curves early, before they progress to an irreversible deformity, and when there is still enough residual growth and remodeling potential.
ApiFix Ltd has developed a novel implant for less invasive treatment of AIS. The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues time to accommodate any incremental correction.
The MID-C System inherent benefits are:
- Only two screws are used
- Incision size is much smaller
- Simpler operation with shorter operative time
- Less complications (attributed to the three points above).
- Minimal spinal mobility loss.
All the device components are made of materials well accepted in the orthopedic field and are fully biocompatible (see Investigator Brochure).
The unique concept of the system and the materials used may provide favorable results as follows: Smaller scare, quicker healing period and better spine mobility over the years.
This study is designed to demonstrate that the MID-C System is safe and effective.
Read the detailed description
The study is designed as an observational study with a 24-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 24-month enrollment period.
- Conditions
- Adolescent Idiopathic Scoliosis (AIS)
- Being tested
- MID-C
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MID-CDevice
The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.
The MID-C System inherent benefits are:
- Only two screws are used
- Incision size is much smaller
- Simpler operation with shorter operative time
- Less complication thanks to the three points above.
- Minimal spinal mobility loss
What is being measured
The primary outcome is the main question the study is designed to answer.
No Device related Serious Adverse Event
Measured: 2 year
No significant curve progression above or below the implant
Measured: 2 years
Secondary outcomes (2)
Minimum of 40% deformity correction within 6 months
Measured: 6 months
Evaluate the correction period by X-ray Evaluate the correction period
Measured: 6 months, 1 year, 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2017
- Study startJun 2014
- Primary completionJul 2016
- Study completionJul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adolescent Idiopathic Scoliosis (AIS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 7 participants (actual)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Apifix
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Yigal Mirovsky, MD, Principal investigator, Asaf Harofe |Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03071471
- Sponsor's protocol ID
- AF-01 Asaf Harofe
- Acronym
- MID-C
- Status last verified
- Feb 2017
- First submitted
- 26 Feb 2017
- Last updated
- 7 Mar 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)
- ClinicalTrials.gov ID
- NCT03071471
- Acronym / sponsor ID
- MID-C / AF-01 Asaf Harofe
- Conditions
- Adolescent Idiopathic Scoliosis (AIS)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 7 participants (actual)
- Lead sponsor
- ApifixIndustry (pharma, biotech, devices)
- Study start
- Jun 2014
- Primary completion
- Jul 2016 (actual)
- Study completion
- Jul 2016 (actual)
- First posted
- 7 Mar 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adolescent idiopathic scoliosis (AIS) is a common disorder of unknown etiology in which the vertebrae and discs gradually develop a curvature that is first detected in patients between 11 and 20 years of age. The deformity is 3-dimensional, with a coronal curve measured from radiographs by the Cobb angle .
The Cobb angle measurement of scoliosis represents the sum of the angular wedging of each vertebra and disc between the superior and inferior end vertebrae . Although a small curve is well tolerated and does not require treatment, a large curve can progress to the point that it is cosmetically unacceptable, interferes with chest wall mechanics, and produces cardiac and pulmonary compromises. The natural history of AIS apparently includes 2 stages: the initiation of the curve and its subsequent progression. The factors responsible for the initiation of the curve are unknown, but the subsequent progression of the curve is clearly associated with the adolescent growth spurt . The primary risk factors for progression include age at onset and the magnitude of the curve; young patients with large curves are at the highest risk .
Although numerous treatment methods have been recommended for patients with AIS, the only accepted treatment includes bracing for skeletally immature patients with curves between 25 and 40 degrees and operative correction with spinal fusion for patients with curves greater than 45 degrees. For many teenagers, the cosmetic and social concerns associated with bracing has caused compliance problems with wearing the brace and many patients only wear the brace at home . While operative intervention completely corrects the scoliosis or rib hump, it eliminates segmental spinal motion, and concentrates stresses at the ends of the fusion potentially leading to disc degeneration and back pain.
Despite satisfactory short-term results of operative instrumentation and fusion, a less invasive technique preserving more motion with a smaller scar represents a major improvement. Realizing this goal is contingent on treating curves early, before they progress to an irreversible deformity, and when there is still enough residual growth and remodeling potential.
ApiFix Ltd has developed a novel implant for less invasive treatment of AIS. The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues time to accommodate any incremental correction.
The MID-C System inherent benefits are:
- Only two screws are used
- Incision size is much smaller
- Simpler operation with shorter operative time
- Less complications (attributed to the three points above).
- Minimal spinal mobility loss.
All the device components are made of materials well accepted in the orthopedic field and are fully biocompatible (see Investigator Brochure).
The unique concept of the system and the materials used may provide favorable results as follows: Smaller scare, quicker healing period and better spine mobility over the years.
This study is designed to demonstrate that the MID-C System is safe and effective.
Detailed description
The study is designed as an observational study with a 24-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 24-month enrollment period.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
Who may qualify
- Ages
- 11 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- The study is designed as a European, observational study with a 12-month follow-up period. Consecutive patients undergoing treatment of AIS by the MID-C system in daily practice will be included during a 6-month enrollment period.
Key inclusion criteria (8 listed)
- Adolescence aged 11 years old to 17 years inclusive
- Minimum of 35 degrees Cobb angle, confirmed by X-ray. Lenke type 1 or 5, with flexible secondary curve.
- Completed at least 6 months of conservative therapy (e.g., P.T., bracing, traction, or others).
- Risser sign of 1 to 4
- Appropriate candidate for posterior surgical approach
Key exclusion criteria (9 listed)
- Cobb angle over 55 degrees
- Other non idiopathic scoliosis.
- AIS which is not defined as Lenke type 1 or 5
- Previous spine surgery.
- Allergy to any component of the device.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MID-CThe MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction. The MID-C System inherent benefits are: * Only two screws are used * Incision size is much smaller * Simpler operation with shorter operative time * Less complication thanks to the three points above. * Minimal spinal mobility loss | Device | – |
Primary outcome
No Device related Serious Adverse Event
Time frame: 2 year
No significant curve progression above or below the implant
Time frame: 2 years
2 secondary outcomes
Minimum of 40% deformity correction within 6 months
Time frame: 6 months
Evaluate the correction period by X-ray Evaluate the correction period
Time frame: 6 months, 1 year, 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2017.
- Individual participant dataSharing planned: No
Related trials for Adolescent Idiopathic Scoliosis (AIS)
Recruiting
Detecting and Monitoring Scoliosis Without Radiography: Standard Radiographic Monitoring Program Versus Self-Screening With Momentum SpineTM
Adolescent Idiopathic Scoliosis
Active, not recruiting
Enhancing the Therapeutic Effect of Bracing for Adolescent Idiopathic Scoliosis With a Hybrid Bracing Protocol
Adolescent Idiopathic Scoliosis (AIS)
RecruitingObservational study
Quality of Life (HRQoL) of AIS Patients Who Require Bracing or Surgery Using SRS-22 Questionnaire
Scoliosis; Adolescence, Adolescent
Not yet recruitingPhase 4
Intravenous Dexamethasone for ESP Block Analgesia in Children Undergoing Idiopathic Scoliosis Surgery
Adolescent Idiopathic Scoliosis (AIS)
RecruitingObservational study
Sleep Quality in Adolescents With Idiopathic Scoliosis
Adolescent, Scoliosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yigal Mirovsky, MD principal investigator
Asaf Harofe |Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Adolescent Idiopathic Scoliosis (AIS), run by Apifix at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
No Device related Serious Adverse Event (time frame: 2 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2017.